|
|
Article: Catalyst Files for $40M IPO To Advance Addiction Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
A company formed in January 2002, based on research conducted at the Brookhaven National Laboratory, filed for an initial public offering to raise $40.25 million - money to support clinical development of its only product, a GABA analog to treat cocaine addiction.
Catalyst Pharmaceutical Partners, of Coral Gables, Fla., did not list the number of shares to be offered or the offering price in its prospectus filed with the SEC. The IPO's underwriters are First Albany Capital and Stifel Nicolaus, both of New York.
The company's lead product, CPP-109, is based on the chemical compound gamma-vinyl-GABA, commonly referred to as ...